USPSTF Recommendation: Screening for Bacterial Vaginosis to Prevent Preterm Delivery | Guidelines | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Screening for Bacterial Vaginosis in Pregnant Persons to Prevent Preterm DeliveryUS Preventive Services Task Force Recommendation Statement

Educational Objective
To review the US Preventive Services Task Force (USPSTF) recommendations regarding screening for bacterial vaginosis in pregnant persons to prevent preterm delivery.
1 Credit CME
Abstract

Importance  Bacterial vaginosis is common and is caused by a disruption of the microbiological environment in the lower genital tract. In the US, reported prevalence of bacterial vaginosis among pregnant women ranges from 5.8% to 19.3% and is higher in some races/ethnicities. Bacterial vaginosis during pregnancy has been associated with adverse obstetrical outcomes including preterm delivery, early miscarriage, postpartum endometritis, and low birth weight.

Objective  To update its 2008 recommendation, the USPSTF commissioned a review of the evidence on the accuracy of screening and the benefits and harms of screening for and treatment of bacterial vaginosis in asymptomatic pregnant persons to prevent preterm delivery.

Population  This recommendation applies to pregnant persons without symptoms of bacterial vaginosis.

Evidence Assessment  The USPSTF concludes with moderate certainty that screening for asymptomatic bacterial vaginosis in pregnant persons not at increased risk for preterm delivery has no net benefit in preventing preterm delivery. The USPSTF concludes that for pregnant persons at increased risk for preterm delivery, the evidence is conflicting and insufficient, and the balance of benefits and harms cannot be determined.

Conclusions and Recommendation  The USPSTF recommends against screening for bacterial vaginosis in pregnant persons not at increased risk for preterm delivery. (D recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for bacterial vaginosis in pregnant persons at increased risk for preterm delivery. (I statement)

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Douglas K. Owens, MD, MS, Stanford University, 615 Crothers Wy, Encina Commons, Mail Code 6019, Stanford, CA 94305-6006 (chair@uspstf.net).

Accepted for Publication: February 21, 2020.

The US Preventive Services Task Force (USPSTF) members: Douglas K. Owens, MD, MS; Karina W. Davidson, PhD, MASc; Alex H. Krist, MD, MPH; Michael J. Barry, MD; Michael Cabana, MD, MA, MPH; Aaron B. Caughey, MD, PhD; Katrina Donahue, MD, MPH; Chyke A. Doubeni, MD, MPH; John W. Epling Jr, MD, MSEd; Martha Kubik, PhD, RN; Gbenga Ogedegbe, MD, MPH; Lori Pbert, PhD; Michael Silverstein, MD, MPH; Melissa A. Simon, MD, MPH; Chien-Wen Tseng, MD, MPH, MSEE; John B. Wong, MD.

Affiliations of The US Preventive Services Task Force (USPSTF) members: Veterans Affairs Palo Alto Health Care System, Palo Alto, California (Owens); Stanford University, Stanford, California (Owens); Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York (Davidson); Fairfax Family Practice Residency, Fairfax, Virginia (Krist); Virginia Commonwealth University, Richmond (Krist); Harvard Medical School, Boston, Massachusetts (Barry); University of California, San Francisco (Cabana); Oregon Health & Science University, Portland (Caughey); University of North Carolina at Chapel Hill (Donahue); Mayo Clinic, Rochester, Minnesota (Doubeni); Virginia Tech Carilion School of Medicine, Roanoke (Epling Jr); Temple University, Philadelphia, Pennsylvania (Kubik); New York University, New York, New York (Ogedegbe); University of Massachusetts Medical School, Worcester (Pbert); Boston University, Boston, Massachusetts (Silverstein); Northwestern University, Evanston, Illinois (Simon); University of Hawaii, Honolulu (Tseng); Pacific Health Research and Education Institute, Honolulu, Hawaii (Tseng); Tufts University School of Medicine, Boston, Massachusetts (Wong).

Author Contributions: Dr Owens had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The USPSTF members contributed equally to the recommendation statement.

Conflict of Interest Disclosures: Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings. Dr Barry reported receiving grants and personal fees from Healthwise.

Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.

Role of the Funder/Sponsor: AHRQ staff assisted in the following: development and review of the research plan, commission of the systematic evidence review from an Evidence-based Practice Center, coordination of expert review and public comment of the draft evidence report and draft recommendation statement, and the writing and preparation of the final recommendation statement and its submission for publication. AHRQ staff had no role in the approval of the final recommendation statement or the decision to submit for publication.

Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.

Additional Contributions: We thank Tina Fan, MD, MPH (AHRQ), who contributed to the writing of the manuscript, and Lisa Nicolella, MA (AHRQ), who assisted with coordination and editing.

Additional Information: The USPSTF makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms. It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment. The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision-making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.

References
1.
Kenyon  C , Colebunders  R , Crucitti  T .  The global epidemiology of bacterial vaginosis: a systematic review.   Am J Obstet Gynecol. 2013;209(6):505-523. doi:10.1016/j.ajog.2013.05.006PubMedGoogle ScholarCrossref
2.
Leitich  H , Kiss  H .  Asymptomatic bacterial vaginosis and intermediate flora as risk factors for adverse pregnancy outcome.   Best Pract Res Clin Obstet Gynaecol. 2007;21(3):375-390. doi:10.1016/j.bpobgyn.2006.12.005PubMedGoogle ScholarCrossref
3.
McGregor  JA , French  JI , Parker  R ,  et al.  Prevention of premature birth by screening and treatment for common genital tract infections: results of a prospective controlled evaluation.   Am J Obstet Gynecol. 1995;173(1):157-167. doi:10.1016/0002-9378(95)90184-1PubMedGoogle ScholarCrossref
4.
Watts  DH , Krohn  MA , Hillier  SL , Eschenbach  DA .  Bacterial vaginosis as a risk factor for post-cesarean endometritis.   Obstet Gynecol. 1990;75(1):52-58.PubMedGoogle Scholar
5.
Hillier  SL , Nugent  RP , Eschenbach  DA ,  et al; Vaginal Infections and Prematurity Study Group.  Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant.   N Engl J Med. 1995;333(26):1737-1742. doi:10.1056/NEJM199512283332604PubMedGoogle ScholarCrossref
6.
Kahwati  LC , Clark  R , Berkman  ND ,  et al  Screening for Bacterial Vaginosis in Pregnant Adolescents and Women to Prevent Preterm Delivery: An Updated Systematic Review for the U.S. Preventive Services Task Force: Evidence Synthesis No. 190. Agency for Healthcare Research and Quality; 2019. AHRQ publication 19-05259-EF-1.
7.
Hamilton  BE , Martin  JA , Osterman  MJ , Rossen  LM . Births: Provisional data for 2018. Vital Statistics Rapid Release No. 7. National Center for Health Statistics; Published 2019. Accessed September 18, 2019. https://www.cdc.gov/nchs/data/vsrr/vsrr-007-508.pdf
8.
Matthews  TJ , MacDorman  MF , Thoma  ME .  Infant mortality statistics from the 2013 period linked birth/infant death data set.   Natl Vital Stat Rep. 2015;64(9):1-30.PubMedGoogle Scholar
9.
Schindler  T , Koller-Smith  L , Lui  K , Bajuk  B , Bolisetty  S ; New South Wales and Australian Capital Territory Neonatal Intensive Care Units’ Data Collection.  Causes of death in very preterm infants cared for in neonatal intensive care units: a population-based retrospective cohort study.   BMC Pediatr. 2017;17(1):59. doi:10.1186/s12887-017-0810-3PubMedGoogle ScholarCrossref
10.
McIntire  DD , Leveno  KJ .  Neonatal mortality and morbidity rates in late preterm births compared with births at term.   Obstet Gynecol. 2008;111(1):35-41. doi:10.1097/01.AOG.0000297311.33046.73PubMedGoogle ScholarCrossref
11.
US Preventive Services Task Force. Procedure Manual. Accessed September 18, 2019. https://www.uspreventiveservicestaskforce.org/Page/Name/procedure-manual
12.
Srinivasan  S , Fredricks  DN .  The human vaginal bacterial biota and bacterial vaginosis.   Interdiscip Perspect Infect Dis. 2008;2008:750479. doi:10.1155/2008/750479PubMedGoogle Scholar
13.
Livengood  CH .  Bacterial vaginosis: an overview for 2009.   Rev Obstet Gynecol. 2009;2(1):28-37.PubMedGoogle Scholar
14.
Bacterial vaginosis treatment and care. Centers for Disease Control and Prevention. Accessed September 18, 2019. https://www.cdc.gov/std/bv/treatment.htm
15.
Allsworth  JE , Peipert  JF .  Prevalence of bacterial vaginosis: 2001-2004 National Health and Nutrition Examination Survey data.   Obstet Gynecol. 2007;109(1):114-120. doi:10.1097/01.AOG.0000247627.84791.91PubMedGoogle ScholarCrossref
16.
Lamont  RF , Sobel  JD , Akins  RA ,  et al.  The vaginal microbiome: new information about genital tract flora using molecular based techniques.   BJOG. 2011;118(5):533-549. doi:10.1111/j.1471-0528.2010.02840.xPubMedGoogle ScholarCrossref
17.
Vodstrcil  LA , Walker  SM , Hocking  JS ,  et al.  Incident bacterial vaginosis (BV) in women who have sex with women is associated with behaviors that suggest sexual transmission of BV.   Clin Infect Dis. 2015;60(7):1042-1053. doi:10.1093/cid/ciu1130PubMedGoogle ScholarCrossref
18.
Schwebke  JR , Desmond  R .  Risk factors for bacterial vaginosis in women at high risk for sexually transmitted diseases.   Sex Transm Dis. 2005;32(11):654-658. doi:10.1097/01.olq.0000175396.10304.62PubMedGoogle ScholarCrossref
19.
Mercer  BM , Goldenberg  RL , Moawad  AH ,  et al; National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network.  The preterm prediction study: effect of gestational age and cause of preterm birth on subsequent obstetric outcome.   Am J Obstet Gynecol. 1999;181(5, pt 1):1216-1221. doi:10.1016/S0002-9378(99)70111-0PubMedGoogle ScholarCrossref
20.
Muglia  LJ , Katz  M .  The enigma of spontaneous preterm birth.   N Engl J Med. 2010;362(6):529-535. doi:10.1056/NEJMra0904308PubMedGoogle ScholarCrossref
21.
Goldenberg  RL , Culhane  JF , Iams  JD , Romero  R .  Epidemiology and causes of preterm birth.   Lancet. 2008;371(9606):75-84. doi:10.1016/S0140-6736(08)60074-4PubMedGoogle ScholarCrossref
22.
Institute of Medicine.  Preterm Birth: Causes, Consequences, and Prevention. National Academies Press; 2007.
23.
Slyker  JA , Patterson  J , Ambler  G ,  et al.  Correlates and outcomes of preterm birth, low birth weight, and small for gestational age in HIV-exposed uninfected infants.   BMC Pregnancy Childbirth. 2014;14:7. doi:10.1186/1471-2393-14-7PubMedGoogle ScholarCrossref
24.
Burtin  P , Taddio  A , Ariburnu  O , Einarson  TR , Koren  G .  Safety of metronidazole in pregnancy: a meta-analysis.   Am J Obstet Gynecol. 1995;172(2, pt 1):525-529. doi:10.1016/0002-9378(95)90567-7PubMedGoogle ScholarCrossref
25.
Caro-Patón  T , Carvajal  A , Martin de Diego  I , Martin-Arias  LH , Alvarez Requejo  A , Rodríguez Pinilla  E .  Is metronidazole teratogenic? a meta-analysis.   Br J Clin Pharmacol. 1997;44(2):179-182. doi:10.1046/j.1365-2125.1997.00660.xPubMedGoogle ScholarCrossref
26.
Diav-Citrin  O , Shechtman  S , Gotteiner  T , Arnon  J , Ornoy  A .  Pregnancy outcome after gestational exposure to metronidazole: a prospective controlled cohort study.   Teratology. 2001;63(5):186-192. doi:10.1002/tera.1033PubMedGoogle ScholarCrossref
27.
Sørensen  HT , Larsen  H , Jensen  ES ,  et al.  Safety of metronidazole during pregnancy: a cohort study of risk of congenital abnormalities, preterm delivery and low birth weight in 124 women.   J Antimicrob Chemother. 1999;44(6):854-856. doi:10.1093/jac/44.6.854PubMedGoogle ScholarCrossref
28.
Czeizel  AE , Rockenbauer  M .  A population based case-control teratologic study of oral metronidazole treatment during pregnancy.   Br J Obstet Gynaecol. 1998;105(3):322-327. doi:10.1111/j.1471-0528.1998.tb10094.xPubMedGoogle ScholarCrossref
29.
Thapa  PB , Whitlock  JA , Brockman Worrell  KG ,  et al.  Prenatal exposure to metronidazole and risk of childhood cancer: a retrospective cohort study of children younger than 5 years.   Cancer. 1998;83(7):1461-1468. doi:10.1002/(SICI)1097-0142(19981001)83:7<1461::AID-CNCR25>3.0.CO;2-1PubMedGoogle ScholarCrossref
30.
US Preventive Services Task Force.  Screening for asymptomatic bacteriuria in adults: US Preventive Services Task Force recommendation statement.   JAMA. 2019;322(12):1188-1194. doi:10.1001/jama.2019.13069PubMedGoogle ScholarCrossref
31.
US Preventive Services Task Force.  Screening for syphilis infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement.   JAMA. 2018;320(9):911-917. doi:10.1001/jama.2018.11785PubMedGoogle ScholarCrossref
32.
US Preventive Services Task Force.  Screening for hepatitis B virus infection in pregnant women: US Preventive Services Task Force reaffirmation recommendation statement.   JAMA. 2019;322(4):349-354. doi:10.1001/jama.2019.9365PubMedGoogle ScholarCrossref
33.
US Preventive Services Task Force.  Screening for HIV infection: US Preventive Services Task Force recommendation statement.   JAMA. 2019;321(23):2326-2336. doi:10.1001/jama.2019.6587PubMedGoogle ScholarCrossref
34.
Kahwati  LC , Clark  R , Berkman  N ,  et al.  Screening for bacterial vaginosis in pregnant adolescents and women to prevent preterm delivery: updated evidence report and systematic review for the US Preventive Services Task Force.   JAMA. Published April 7, 2020. doi:10.1001/jama.2020.0233Google Scholar
35.
Kekki  M , Kurki  T , Pelkonen  J , Kurkinen-Räty  M , Cacciatore  B , Paavonen  J .  Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial.   Obstet Gynecol. 2001;97(5, pt 1):643-648.PubMedGoogle Scholar
36.
Kiss  H , Petricevic  L , Husslein  P .  Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery.   BMJ. 2004;329(7462):371. doi:10.1136/bmj.38169.519653.EBPubMedGoogle ScholarCrossref
37.
Lamont  RF , Duncan  SL , Mandal  D , Bassett  P .  Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora.   Obstet Gynecol. 2003;101(3):516-522.PubMedGoogle Scholar
38.
Ugwumadu  A , Manyonda  I , Reid  F , Hay  P .  Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial.   Lancet. 2003;361(9362):983-988. doi:10.1016/S0140-6736(03)12823-1PubMedGoogle ScholarCrossref
39.
Carey  JC , Klebanoff  MA , Hauth  JC ,  et al; National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.  Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis.   N Engl J Med. 2000;342(8):534-540. doi:10.1056/NEJM200002243420802PubMedGoogle ScholarCrossref
40.
McDonald  HM , O’Loughlin  JA , Vigneswaran  R ,  et al.  Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial.   Br J Obstet Gynaecol. 1997;104(12):1391-1397. doi:10.1111/j.1471-0528.1997.tb11009.xPubMedGoogle ScholarCrossref
41.
Subtil  D , Brabant  G , Tilloy  E ,  et al.  Early clindamycin for bacterial vaginosis in pregnancy (PREMEVA): a multicentre, double-blind, randomised controlled trial.   Lancet. 2018;392(10160):2171-2179. doi:10.1016/S0140-6736(18)31617-9PubMedGoogle ScholarCrossref
42.
Larsson  PG , Fåhraeus  L , Carlsson  B , Jakobsson  T , Forsum  U ; Premature Study Group of the Southeast Health Care Region of Sweden.  Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen.   BJOG. 2006;113(6):629-637. doi:10.1111/j.1471-0528.2006.00946.xPubMedGoogle ScholarCrossref
43.
Guaschino  S , Ricci  E , Franchi  M ,  et al.  Treatment of asymptomatic bacterial vaginosis to prevent pre-term delivery: a randomised trial.   Eur J Obstet Gynecol Reprod Biol. 2003;110(2):149-152. doi:10.1016/S0301-2115(03)00107-6PubMedGoogle ScholarCrossref
44.
McGregor  JA , French  JI , Jones  W ,  et al.  Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream.   Am J Obstet Gynecol. 1994;170(4):1048-1059. doi:10.1016/S0002-9378(94)70098-2PubMedGoogle ScholarCrossref
45.
Hauth  JC , Goldenberg  RL , Andrews  WW , DuBard  MB , Copper  RL .  Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis.   N Engl J Med. 1995;333(26):1732-1736. doi:10.1056/NEJM199512283332603PubMedGoogle ScholarCrossref
46.
Morales  WJ , Schorr  S , Albritton  J .  Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study.   Am J Obstet Gynecol. 1994;171(2):345-347. doi:10.1016/S0002-9378(94)70033-8PubMedGoogle ScholarCrossref
47.
Vermeulen  GM , Bruinse  HW .  Prophylactic administration of clindamycin 2% vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo-controlled double-blind trial.   Br J Obstet Gynaecol. 1999;106(7):652-657. doi:10.1111/j.1471-0528.1999.tb08363.xPubMedGoogle ScholarCrossref
48.
Committee on Practice Bulletins—Obstetrics, The American College of Obstetricians and Gynecologists.  Practice bulletin no. 130: prediction and prevention of preterm birth.   Obstet Gynecol. 2012;120(4):964-973. doi:10.1097/AOG.0b013e3182723b1bPubMedGoogle ScholarCrossref
49.
Workowski  KA , Bolan  GA ; Centers for Disease Control and Prevention.  Sexually transmitted diseases treatment guidelines, 2015.   MMWR Recomm Rep. 2015;64(RR-03):1-137.PubMedGoogle Scholar
50.
Clinical preventive service recommendation: bacterial vaginosis. American Academy of Physicians. Accessed September 18, 2019. https://www.aafp.org/patient-care/clinical-recommendations/all/bacterial-vaginosis.html
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close